Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: The Boots Company PLC, 1 Thane Road West, Nottingham, NG2 3AA Trading as: BCM
Hypersensitivity to any of the ingredients, patients with cardiovascular disease, hyperthyroidism, angle closure glaucoma or prostatic enlargement.
Keep away from the eyes.
Not to be used for children under 12 years without medical advice.
The spray should not be used in excess of the stated dosage nor for longer than seven days without medical advice.
Keep all medicines out of the reach of children.
Boots Nasal Spray should not be given to patients being treated with monoamine oxidase inhibitors or within 14 days of ceasing such treatment.
The safety of Boots Nasal Spray during pregnancy and lactation has not been established, but is not thought to constitute a hazard during these periods.
No adverse effects known.
Occasionally may cause local irritation and dryness of the mouth and throat.
Prolonged use may cause rebound congestion and rhinitis medicamentosa.
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Not applicable.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
